Clinical Trial Update: Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing pharmacodynamic noninferiority of Efgartigimod PH20 SC versus IV in generalized myasthenia gravis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis | Phase 3 | Status: COMPLETED | Results posted: 2023-02-28